ArticleBMC infectious diseases2020
Factors associated with cytomegalovirus serostatus in young people in England: a cross-sectional study.
Article in BMC infectious diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.
- Association Between Cytomegalovirus Infection and Tuberculosis Disease: A Systematic Review and Meta-Analysis of Epidemiological Studies.The Journal of infectious diseases · 2023Pooled it
- Seroprevalence and risk factors of cytomegalovirus infection in pregnant women in Lebanon: A retrospective study conducted at Hôtel-Dieu de France.IJID regions · 2026Article
- CMV primary and non-primary infections among daycare workers, and development of strategies to prevent infection (EDUQ-CMV): a mixed-method study protocol.BMC infectious diseases · 2025Observational
- The indirect effects of cytomegalovirus infection-mechanisms and consequences.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2025Article
- Acyclic graphs to define models of relationships between human cytomegalovirus, cardiovascular disease and all-cause mortality in UK Biobank.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2025Article
- Does cytomegalovirus infection increase the risk of tuberculosis in UK children?Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2025Observational
- Cytokine levels in breast cancer are highly dependent on cytomegalovirus (CMV) status.Breast cancer research and treatment · 2024Article
- Epidemiological characteristics of three herpesviruses infections in children in Nanjing, China, from 2018 to 2023.Frontiers in cellular and infection microbiology · 2024Article
- Cytomegalovirus infection may be oncoprotective against neoplasms of B-lymphocyte lineage: single-institution experience and survey of global evidence.Virology journal · 2022Article
- Human Cytomegalovirus and Risk of Incident Cardiovascular Disease in UK Biobank.The Journal of infectious diseases · 2022Article
- Epidemiological and Liver Biomarkers Profile of Epstein-Barr Virus Infection and Its Coinfection with Cytomegalovirus in Patients with Hematological Diseases.Biomolecules · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 6 institutions in 2 countries.
Funding
Abstract
backgroundHuman cytomegalovirus (CMV) is a common herpesvirus which is estimated to infect 83% of the global population. Whilst many infections are asymptomatic, it is an important cause of morbidity and mortality, particularly for immunocompromised people and for infants who are congenitally infected. A vaccine against CMV has been stated as a public health priority, but there are gaps in our understanding of CMV epidemiology. To guide potential future vaccination strategies, our aim was to examine risk factors for CMV seropositivity in young people in England.
methodsThe Health Survey for England (HSE) is an annual, cross-sectional representative survey of households in England during which data are collected through questionnaires, and blood samples are taken. We randomly selected individuals who participated in the HSE 2002, aiming for 25 participants of each sex in each single year age group from 11 to 24 years. Stored samples were tested for CMV antibodies. We undertook descriptive and regression analyses of CMV seroprevalence and risk factors for infection.
resultsDemographic data and serostatus were available for 732 individuals, of whom 175 (23.7%) were CMV-seropositive. CMV seroprevalence was associated with age, with 18.3% seropositive at 11-14 years compared to 28.3% at 22-24 years. CMV serostatus was also higher in people of non-white ethnicity (adjusted odds ratio [aOR] 6.22, 95% confidence interval [CI] 3.47-11.14), and in adults who were seropositive for EBV (aOR 2.08 [1.06-4.09]). There was no evidence that smoking status, occupation, body mass index and region of England were associated with CMV serostatus.
conclusionsCMV seroprevalence is strongly associated with ethnicity, and modestly increases with age in 11-24-year-olds. A greater understanding of the transmission dynamics of CMV, and the impact of this on CMV-associated morbidity and mortality, is necessary to inform effective vaccination strategies when a vaccine for CMV becomes available.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.